Rhythm Pharmaceuticals Inc RYTM

$92.83 -0.58 (-0.62%)

Valuation

Market cap
6,401,667,000
Revenue TTM
$189,760,000
Net income TTM
$-196,540,000
PE ratio
0.00
Forward PE
—
Profit margin
-103.57%
Debt to equity
0.00

Trading

Volume
503,500
Avg volume
652,916
Day's range
$92.66 – $95.32
Shares out
68,533,000
Stochastic %K
2%
Beta
2.01
Analysts
Strong Sell
Price target
$139.72

Price

Company profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alst...

Show more

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 264 4280
Website
https://rhythmtx.com
Address
222 Berkeley Street, 12th Floor, Boston, United States

Latest news

Stocktwits

abcdzepeda Oct 3, 5:29 PM
$RYTM you’re killing me here! 
0 replies
Stonky_Mcprofitface Oct 2, 10:25 AM
$RYTM Going down again. Could hit the $70S.
0 replies
Quantumup Oct 1, 12:55 PM
Stifel reiterated $AMLX Buy; PT $45 $CRNX VRTX $RYTM MBX VOGX ASND RICFY ZLDPF ZLDPY RZLT Here's what Stifel said in its note: https://x.com/Quantumup1/status/2105642692264731118?s=20
0 replies
Stonky_Mcprofitface Sep 22, 12:14 PM
$RYTM Meeker selling because…he’s in discussions to sell the company?
2 replies
profitraider Sep 15, 9:55 PM
$RYTM Second leg down in play… see ya at 60!
1 replies
WallStWireAds Sep 15, 12:48 PM
$PTN GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach. $RYTM $LLY $VKTX https://www.benzinga.com/content/61786779/glp-1s-transformed-obesity-billions-are-now-moving-rare-diseases-require-different-approach
0 replies
Stonky_Mcprofitface Sep 11, 2:20 PM
$RYTM Been in this since $6. Stalled a bit here but it will head higher.
0 replies
JFDI Sep 11, 12:18 PM
$RYTM Weekly Base
0 replies